Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 268
  • Print this page
  • Email this page
This article has been cited by
1Re: Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection. Am J Ther. 2022;29:e232.
Andrew Bryant,Theresa A. Lawrie,Edmund J. Fordham,Scott Mitchell
American Journal of Therapeutics.2022;29(4)455
2Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysauto-nomia
Hayder M. Al-kuraishy,Ali I. Al-Gareeb,Athanasios Alexiou,Gaber El-Saber Batiha
Current Drug Targets.2022;23(13)1277
3Ivermectin for preventing and treating COVID-19
Maria Popp,Stefanie Reis,Selina Schießer,Renate Ilona Hausinger,Miriam Stegemann,Maria-Inti Metzendorf,Peter Kranke,Patrick Meybohm,Nicole Skoetz,Stephanie Weibel
Cochrane Database of Systematic Reviews.2022;2022(6)1277
4Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock,Kurt D. Weber,Philip A. Giordano,Mitchell D. Barneck
American Journal of Therapeutics.2022;29(2)e237
5Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021
Martin Ho,Mina Tadrous,Anita Iacono,Katie Suda,Tara Gomes
Journal of Antimicrobial Chemotherapy.2022;29(2)e237
6Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status
Nirmeen Sabry,Yasser Fouad,Mohamed AbdAllah,Ahmed Cordie,Gamal Esmat
American Journal of Therapeutics.2022;Publish Ahead of Print(2)e237
7Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19)
Adarsh Bhimraj,Rebecca L Morgan,Amy Hirsch Shumaker,Lindsey R Baden,Vincent Chi-Chung Cheng,Kathryn M Edwards,Jason C Gallagher,Rajesh T Gandhi,William J Muller,Mari M Nakamura,John C O’Horo,Robert W Shafer,Shmuel Shoham,M Hassan Murad,Reem A Mustafa,Shahnaz Sultan,Yngve Falck-Ytter
Clinical Infectious Diseases.2022;Publish Ahead of Print(2)e237
8Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang,Huaqing Jin,Yi Feng Wen,Guosheng Yin
Frontiers in Public Health.2021;9(2)e237
9Phenolic compounds versus SARS-CoV-2: An update on the main findings against COVID-19
Vicente Amirpasha Tirado-Kulieva,Ernesto Hernández-Martínez,Tania Jakeline Choque-Rivera
10The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable
Jack M. Lawrence,Gideon Meyerowitz-Katz,James A. J. Heathers,Nicholas J. L. Brown,Kyle A. Sheldrick
Nature Medicine.2021;27(11)1853
11Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Andrew Hill,Manya Mirchandani,Victoria Pilkington
Open Forum Infectious Diseases.2022;9(2)1853
12A Survey for Predictors of Mortality among COVID-19 Patients: A Retrospective Study from Iran
arezoo monfared,mohammad taghi moghadamnia,Samad Karkhah,saman maroufizadeh,Mohammad Asadian Rad,Jalal kheirkhah,fatemeh jafaraghayee
Jorjani Biomedicine Journal.2021;9(4)13
13Re: “Commentary” by Rothrock et al. “Meta-Analyses Did Not Establish Improved Mortality With Ivermectin Use in COVID-19”
Andrew Bryant,Theresa A. Lawrie,Edmund J. Fordham,Scott Mitchell
American Journal of Therapeutics.2022;29(2)e233
14Identification and Development of Therapeutics for COVID-19
Halie M. Rando,Nils Wellhausen,Soumita Ghosh,Alexandra J. Lee,Anna Ada Dattoli,Fengling Hu,James Brian Byrd,Diane N. Rafizadeh,Ronan Lordan,Yanjun Qi,Yuchen Sun,Christian Brueffer,Jeffrey M. Field,Marouen Ben Guebila,Nafisa M. Jadavji,Ashwin N. Skelly,Bharath Ramsundar,Jinhui Wang,Rishi Raj Goel,YoSon Park,Simina M. Boca,Anthony Gitter,Casey S. Greene,Jack A. Gilbert
15Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Abolfazl Akbari,Mahya Razmi,Alireza Sedaghat,Seyyed Mohammad Matin Alavi Dana,Mahdi Amiri,Ali Mohammad Halvani,Soroush Yazdani,Sajad Sahab-Negah
Expert Review of Anti-infective Therapy.2022;20(4)585
16Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study
Morteza Shakhsi Niaee,Leila Zolghadr,Zahra Hosseinkhani,Peyman Namdar,Abbas Allami,Fatemeh Amini,Mehran Varnaseri,Allieh Pourdast,Nematollah Gheibi
Iranian Journal of Science and Technology, Transactions A: Science.2022;46(5)1369
17Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock,Kurt D. Weber,Philip A. Giordano,Mitchell D. Barneck
American Journal of Therapeutics.2022;29(1)e87
18Bayesian Hypothesis Testing and Hierarchical Modeling of Ivermectin Effectiveness
Martin Neil,Norman Fenton
American Journal of Therapeutics.2021;28(5)e576
19Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey
Estefanía Calvo-Alvarez,Maria Dolci,Federica Perego,Lucia Signorini,Silvia Parapini,Sarah D’Alessandro,Luca Denti,Nicoletta Basilico,Donatella Taramelli,Pasquale Ferrante,Serena Delbue
20Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients
Arman Shafiee,Mohammad Mobin Teymouri Athar,Omid Kohandel Gargari,Kyana Jafarabady,Sepehr Siahvoshi,Sayed-Hamidreza Mozhgani
Virology Journal.2022;19(1)1284
21Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino,Karina Cardoso Meira,Nathalia Sernizon Guimarães,Paula Perdigão Motta,Victor Schulthais Chagas,Silvana Márcia Bruschi Kelles,Laura Caetano de Sá,Reginaldo Aparecido Valacio,Patrícia Klarmann Ziegelmann
BMC Infectious Diseases.2022;22(1)1284